PUBLIC CONTRACT · 2022
Medicamentos Certolizumab pegol, Everolímus, Nusinersen (SPMS)
- Contract value
- €293,544.81
- Signed on
- 1 January 2022
- Procedure
- Ao abrigo de acordo-quadro (art.º 259.º)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 9185072PUBLISHED DESCRIPTION
41/48/2022
WHO CONTRACTED
Parties involved
- Awardee
- NOVARTIS FARMA-PRODUT.FARMACEUTICOS, SA; UCB PHARMA PRODUTOS FARMACEUTICOS, LDA; BIOGEN PORTUGAL, SOC FARMACÊUTICA, UNIPESSOAL
- Place of performance
- Portugal
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- NOVARTIS FARMA-PRODUT.FARMACEUTICOS, SA · Tax ID 500063524
- Awardee
- UCB PHARMA PRODUTOS FARMACEUTICOS, LDA · Tax ID 500291322
- Awardee
- BIOGEN PORTUGAL, SOC FARMACÊUTICA, UNIPESSOAL · Tax ID 506415740
HOW MUCH AND WHEN
Values and timeline
- Contract price
- €293,544.81
- Procedure base price
- €0.00
- Total effective price
- Not reported on Portal BASE
- Publication date
- 14 April 2022
- Award date
- 21 October 2021
- Signing date
- 1 January 2022
- Performance period
- 90 days
The contract price is the value agreed in the contract, not the amount paid.
HOW IT WAS CONTRACTED
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Ao abrigo de acordo-quadro (art.º 259.º)
- Award criterion
- Monofator
- CPV code
- 33690000-3 - Medicamentos vários
- Legal basis
- Artigo 259.º do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos (DL111-B/2017) e Lei n.º 30/2021, de 21.05
- Framework agreement
- CP 2019/61 - Medicamentos diversos
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 5451299
KEEP EXPLORING
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.